1997 Royal College mealist in medicine

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS112
Academic Journal
Presents an abstract of the research manuscript `Experimental investigation of levodopa-induced dyskinesia in a primate model of Parkinsonism,' by P.J. Blanchet.


Related Articles

  • Actions of the D[sub 1] agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Pearce, R. K. B.; Jackson, M.; Britton, D. R.; Shiosaki, K.; Jenner, P.; Marsden, C. D. // Psychopharmacology;1999, Vol. 142 Issue 1, p51 

    Abstract Common marmosets show parkinsonian motor deficits following 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) administration and develop dyskinesias during chronic L-dopa exposure. The D[sub l] agonists A-77636 [(1R, 3S) 3-(l'-adamantyl)-l-aminomethyl-3, 4-dihydro-5,...

  • Resolution of dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Caradoc-Davies, T.H. // British Medical Journal (Clinical Research Edition);7/5/1986, Vol. 293 Issue 6538, p38 

    Investigates the dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Difficulty of diagnosing thyrotoxins; Complications of treatment with compounds containing levodopa; Response of patients to the thyrotrophin releasing hormone...

  • Questions and answers about Parkinson's disease.  // Patient Care;Sep2006, Vol. 40 Issue 9, p39 

    The article presents facts about Parkinson's disease (PD). Among the main symptoms of PD are abnormal shaking or tremor, slowness of movements and muscle stiffness or rigidity. Levodopa is the most important medicine for the treatment of PD. Regular exercise and physical therapy can help in...

  • Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease. Hood, Ashley J.; Amador, Silvia C.; Cain, Ashley E.; Briand, Kevin A.; Al-Refai, Ali H.; Schiess, Mya C.; Sereno, Anne B. // Journal of Neurology, Neurosurgery & Psychiatry;Jun2007, Vol. 78 Issue 6, p565 

    Background: The integrity of frontal systems responsible for voluntary control and their interaction with subcortical regions involved in reflexive responses were studied in patients with Parkinson's disease (PD). Previous studies have shown that patients with PD have impaired executive...

  • Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Thanvi, Bhomraj; Lo, Nelson; Robinson, Tom // Postgraduate Medical Journal;Jun2007, Vol. 83 Issue 980, p384 

    Levodopa is the most effective drug for treating Parkinson's disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa...

  • Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease: a study using a video motion analysis system. Krystkowiak, Pierre; Blatt, Jean Louis; Bourriez, Jean Louis; Duhamel, Alain; Perina, Myriam; Kemoun, Gilles; Blond, Serge; Guieu, Jean Daniel; Dest�e, Alain; Defebvre, Luc // Journal of Neurology;Nov2001, Vol. 248 Issue 11, p944 

    Chronic bilateral internal globus pallidus (GPi) stimulation allows control of levodopa induced dyskinesias (LID) and motor symptoms in severe Parkinson's disease (PD). The effect on gait has not been clearly established. Different results have been reported, mostly consisting of clinical data....

  • An update on the management of young-onset Parkinson's disease. Klepac, Nataša; Habek, Mario; Adamec, Ivan; Barušic, Anabella Karla; Bach, Ivo; Margetic, Eduard; Lušic, Ivo // Degenerative Neurological & Neuromuscular Disease;2013, Vol. 3, p53 

    In the text that follows, we review the main clinical features, genetic characteristics, and treatment options for Parkinson's disease (PD), considering the age at onset. The clinical variability between patients with PD points at the existence of subtypes of the disease. Identification of...

  • Pramipexole + Levodopa in Parkinson's Disease: Is the Whole Greater than the Sum of its Parts? Nirenberg, Melissa J. // Neurology Alert;Mar2010, Vol. 28 Issue 7, p52 

    LEVODOPA AND DOPAMINE AGONISTS (DAS) ARE commonly used treatments for Parkinson's disease (PD). Although DAs tend to have more side effects than levodopa, they are often favored as initial therapy because this strategy delays the onset of motor complications such as wearing off and dyskinesias....

  • Levodopa Response and Prognosis in Parkinson's Disease. Henchcliffe, Claire // Neurology Alert;Sep2007, Vol. 26 Issue 1, p5 

    The authors identified 97 autopsy-proven Parkinson's disease (PD) cases from the Queen's Square Brain Bank between 2001 and 2006, all with long-term levodopa treatment and rigorous clinical documentation. Clinical features were evaluated by chart review. Cerebral pathology was determined by:...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics